Studies Confirm Efficacy and Safety of Sidenafil Citrate in Treatment of Erectile Dysfunction Under Proper Guidelines

ข่าวทั่วไป Tuesday October 31, 2000 13:47 —PRESS RELEASE LOCAL

Bangkok--Oct 31--Shandwick International (Thailand)
The results of two recently published studies by leading medical authorities have confirmed the effectiveness of sildenafil citrate in the treatment of Erectile Dysfunction (ED).
The first study headed by Dr. S. D. Katz and conducted by the Division of Circulatory Physiology, and Division of Cardiology, Columbia University, New York looked at the effects of sildenafil citrate on the arterial blood flow of patients with chronic heart failure.
Most doctors now accept that erectile dysfunction (ED) and certain types of heart disease share many of the same risk factors and often co-exist. Earlier studies have also confirmed that the prevalence of ED in patients with cardiovascular disease is higher than that in the general population.
The New York research studied 39 men and 9 women with symptomatic congestive heart failure. Eight men and 4 women with no history of heart disease served as a control group to provide a comparison for treatment and measurements. The study, during which 3 increasingly larger doses of sildenafil citrate were given to the patients, demonstrated that a single 25mg and 50mg oral dose of sildenafil citrate acutely increased flow-mediated endothelium-dependent vasodilation in patients with chronic heart failure. In other words their arterial blood flow was improved very quickly. Sildenafil was also reported as being well tolerated in the study group without inducing significant changes in heart rate or blood pressure.
The second study conducted under the auspices of the Princeton Consensus Conference was prompted by the high incidence of cardiovascular disease in patients seeking treatment for erectile dysfunction and the need to develop clinical guidelines for patient management. The study which looked at a wide range of medical conditions associated with heart disease also proposed simple guidelines for physicians in the clinical management of patients with varying degrees of cardiac risk. Recommendations included the routine assessment of sexual function in the initial evaluation of all patients.
Further evaluation should also be undertaken to classify patients in relation to high, intermediate, or low levels of cardiac risk. The majority of patients at low risk may be safely encouraged to engage in or resume sexual activity or receive treatment for sexual dysfunction as needed. High risk patients should be stabilised by cardiologic treatment before resumption of sexual activity or treatment for sexual dysfunction is given. In all cases, patient follow-up at regular intervals is recommended.
The study concludes that current therapies for ED and other sexual dysfunctions are safe and effective in the majority of patients with or without cardiovascular disease, although the contraindication for sildenafil in patients taking nitrates should always be observed.
Sexual function is an important component of patients'quality of life and subjective well being. Recent epidemiologic data reveal that sexual problems are widespread and adversely affect mood, well-being, and interpersonal functioning. Common sexual problems include disorders of desire, and disorders of arousal and/or erections and disorders of orgasm and ejaculation.
For free literature and consultations, please contact The Information Centre on Men's Health (ICMH) Tel 635-1001; fax 656 8455 or PO Box 2513, Bangkok 10501 or http://menhealth.pfizer.co.th. All letters and questions sent to the Centre will be treated in strictest confidence.
For further information, please contact: Pongprach Surojnametakul
Nilobol Kowahpitaktes
Shandwick International (Thailand) Ltd.
Tel: 257 0300 Fax: 257 0312 End.
-AN-

แท็ก thailand   Bangkok   nation   Prince   AFET   ATIC  

เว็บไซต์นี้มีการใช้งานคุกกี้ ศึกษารายละเอียดเพิ่มเติมได้ที่ นโยบายความเป็นส่วนตัว และ ข้อตกลงการใช้บริการ รับทราบ